Loading...
•
Mar 31
Nano-X Q1 2025 Earnings Report
Nanox reported a wider net loss despite higher revenue in Q1 2025.
Key Takeaways
Nanox posted a net loss of $13.2M for Q1 2025, with revenue reaching $2.8M. The company received FDA clearance for its updated ARC X system and continued expanding its commercial deployments.
Revenue increased to $2.8M from $2.6M in Q1 2024.
Net loss widened to $13.2M from $12.2M year-over-year.
Received FDA 510(k) clearance for Nanox.ARC X.
Deployed over 60 imaging units across commercial and clinical settings.
Nano-X
Nano-X
Nano-X Revenue by Segment
Revenue by Segment
Teleradiology Revenue
CapyFin.comImaging Products Revenue
CapyFin.comAI Solutions Revenue
CapyFin.com Forward Guidance
Nanox expects to increase deployment of units globally to over 100 by year-end, assuming stable macroeconomic conditions.
Positive Outlook
- Targeting over 100 units deployed globally by end of 2025
- Continued strong performance in teleradiology services
- Commercial collaborations to support growth
- FDA clearance for Nanox.ARC X enhances credibility
- Strengthened regulatory and clinical foundation for products
Challenges Ahead
- Ongoing operating losses continue to be significant
- Negative cash flow from operations of $10.3M
- Gross loss margin remains heavily negative on GAAP basis
- Revenue from imaging systems remains minimal
- Dependence on further commercialization to scale revenues
Revenue & Expenses
Visualization of income flow from segment revenue to net income